CJC-1295 (With DAC and Without DAC) - Comprehensive Research Paper

Executive Summary

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of 30 amino acids, designed to stimulate growth hormone (GH) secretion from the pituitary gland. The peptide exists in two distinct forms that are often confused but have dramatically different pharmacokinetic profiles and clinical applications:

1. CJC-1295 WITH DAC (Drug Affinity Complex): Long-acting version with 6-8 day half-life, producing sustained GH elevation
2. CJC-1295 WITHOUT DAC (also called Modified GRF 1-29 or Mod GRF 1-29): Short-acting version with 30-minute half-life, producing pulsatile GH release

Understanding the difference between these two versions is critical for safe and effective use. The WITH DAC version was investigated in clinical trials but development was discontinued following a subject death (though not conclusively linked to the peptide). The WITHOUT DAC version is more commonly used today, especially in combination with ipamorelin, because it mimics natural pulsatile GH secretion.

1. Chemical Structure and Composition

1.1 Base Structure (Applies to Both Versions)

CJC-1295 (Modified GHRH 1-29):

• Molecular Formula: C₁₆₅H₂₇₁N₄₇O₄₆ (without DAC)
• Amino Acid Length: 29-30 amino acids (depending on whether DAC is attached)
• Classification: Synthetic GHRH analog
• Base Sequence: Modified growth hormone-releasing factor (GRF)

Full Amino Acid Sequence (Without DAC):

Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂

1.2 Strategic Amino Acid Modifications from Natural GHRH

CJC-1295 incorporates four critical amino acid substitutions from the original endogenous GHRH sequence, specifically designed to enhance stability and resistance to enzymatic degradation:

Position 2: L-Alanine → D-Alanine

• D-amino acid resists degradation by dipeptidyl peptidase-4 (DPP-4)
• DPP-4 normally cleaves natural GHRH within minutes
• This single modification extends half-life from <5 minutes to 30 minutes (without DAC)

Position 8: Asparagine (Asn) → Glutamine (Gln)

• Prevents deamidation (conversion of Asn to aspartic acid)
• Deamidation causes loss of biological activity
• Enhances long-term stability in solution

Position 15: Glycine (Gly) → Alanine (Ala)

• Increases α-helical stability
• Helical structure is critical for GHRH receptor binding
• Enhances potency at receptor

Position 27: Methionine (Met) → Leucine (Leu)

• Eliminates oxidation-prone methionine
• Methionine oxidation inactivates peptide
• Improves stability during storage

C-Terminal Amidation (-NH₂):

• Prevents carboxypeptidase degradation
• Carboxypeptidases would otherwise cleave C-terminal amino acids
• Essential for biological activity

1.3 Drug Affinity Complex (DAC) - The Critical Difference

What is DAC?

The Drug Affinity Complex (DAC) is a chemical modification added to the lysine residue at position 30 of CJC-1295. Specifically, DAC consists of a maleimidopropionyl group that binds covalently to serum albumin after injection.

Chemical Structure of DAC:

• IUPAC Nomenclature: Nɛ30-maleimidopropionyl-[D-Ala², Gln⁸, Ala¹⁵, Leu²⁷]-GHRH(1-29)
• Functional Group: Maleimide (reactive moiety)
• Linker: Propionyl spacer
• Attachment Site: Lysine-30 epsilon amino group

Mechanism of DAC:

1. After subcutaneous injection, CJC-1295 + DAC enters bloodstream
2. The maleimide group on DAC reacts with cysteine residues on serum albumin
3. CJC-1295 becomes covalently bound to albumin (the most abundant plasma protein)
4. Albumin-bound CJC-1295 has very slow clearance (albumin half-life ~19 days)
5. CJC-1295 is slowly released from albumin, providing sustained GHRH activity

Result:

• With DAC: Half-life extended to 6-8 days (continuous GH elevation)
• Without DAC: Half-life remains ~30 minutes (pulsatile GH release)

1.4 Nomenclature Confusion (VERY IMPORTANT)

Critical Naming Issue:

The peptide community uses confusing and sometimes inconsistent terminology:

| Term | Actual Peptide | Half-Life | Typical Use | |---

Goal Relevance:

• Enhance muscle growth and strength gains by stimulating natural growth hormone release.
• Support fat loss and improve body composition through increased metabolic activity.
• Aid in post-surgical recovery and tissue repair by promoting growth hormone secretion.
• Boost energy levels and overall vitality by optimizing hormone function.
• Improve sleep quality and recovery by regulating growth hormone cycles.
• Support anti-aging efforts by enhancing skin health and cellular repair.
• Assist in joint pain relief and improved mobility through growth hormone benefits.
• Enhance libido and sexual wellness by balancing hormone levels.

Goal Archetype Integration

CJC-1295 addresses multiple optimization archetypes through its primary mechanism of enhancing endogenous growth hormone release. Understanding which version (WITH DAC vs WITHOUT DAC) aligns with specific goals is critical for protocol design.

GH Release Optimization

Primary Application: Restoring youthful GH pulsatility in adults with age-related decline.

Mechanism Alignment:

• CJC-1295 WITHOUT DAC (Mod GRF 1-29) is preferred for GH release optimization
• Preserves natural pulsatile secretion pattern (mimics endogenous GHRH)
• Synergistic with GHRPs (ipamorelin) for amplified GH pulses (3-5x greater than either alone)

Target Outcomes:

• Restoration of youthful GH pulse amplitude
• Normalization of nocturnal GH surge
• IGF-1 elevation to age-appropriate upper tertile

Protocol Recommendation: CJC-1295 WITHOUT DAC 100-200 mcg + Ipamorelin 200-300 mcg, administered 30-60 minutes before sleep.

Recovery Enhancement

Primary Application: Accelerating post-exercise recovery, injury healing, and surgical recovery.

Mechanism Alignment:

• GH/IGF-1 stimulates collagen synthesis (tendons, ligaments, skin)
• Enhances muscle protein synthesis and nitrogen retention
• Promotes cartilage repair and bone remodeling
• Supports immune function during recovery periods

Target Outcomes:

• Reduced delayed-onset muscle soreness (DOMS)
• Faster return to training after intense sessions
• Improved wound healing and tissue regeneration
• Enhanced post-surgical recovery (off-label)

Protocol Recommendation: CJC-1295 WITHOUT DAC + Ipamorelin combination, twice daily (post-workout + bedtime) for enhanced recovery stimulus. Consider 8-12 week cycle during intensive training blocks or recovery periods.

Anti-Aging and Longevity

Primary Application: Mitigating age-related decline in GH/IGF-1 axis function.

Mechanism Alignment:

• GH secretion declines approximately 14% per decade after age 30
• Reduced IGF-1 associated with sarcopenia, osteopenia, cognitive decline
• CJC-1295 restores GH secretion without exogenous GH administration
• Preserves hypothalamic-pituitary feedback (unlike rhGH)

Target Outcomes:

• Improved skin elasticity and reduced wrinkles (collagen synthesis)
• Enhanced sleep quality and depth (GH pulse timing)
• Maintenance of lean body mass
• Improved energy and vitality
• Better cognitive function (neuroprotective effects of IGF-1)

Protocol Recommendation: Conservative dosing (100 mcg CJC-1295 WITHOUT DAC nightly) for long-term use. Focus on maintaining IGF-1 in age-appropriate upper tertile rather than supraphysiological elevation. Prioritize cycling (8-12 weeks on, 4 weeks off) for sustained receptor sensitivity.

Body Composition Optimization

Primary Application: Improving lean mass to fat mass ratio through GH-mediated metabolic effects.

Mechanism Alignment:

• GH promotes lipolysis (fat breakdown) via hormone-sensitive lipase activation
• IGF-1 enhances muscle protein synthesis (anabolic)
• Combined effect: Simultaneous fat loss and lean mass preservation/gain
• GH effects on visceral adipose tissue particularly pronounced
• Enhanced nutrient partitioning (calories preferentially toward muscle vs fat)

Target Outcomes:

• 1-3% body fat reduction over 8-12 week cycle (realistic expectation)
• Preservation or modest gain in lean body mass (0.5-2 lbs/month)
• Improved body fat distribution (reduced visceral fat)
• Enhanced muscle definition and tone
• Waist circumference reduction (1-2 inches over 12 weeks)

Protocol Recommendation: CJC-1295 WITHOUT DAC + Ipamorelin combination with twice daily dosing (AM fasted + PM before bed) for maximum lipolytic and anabolic stimulus. Requires strict fasting protocols around injections (90-120 min before, 30-60 min after). Best results when combined with resistance training and caloric deficit or maintenance.

Practical Biohacker Implementation: Body Recomposition Stack

Complete 12-Week Body Recomposition Protocol:

Week 0: Baseline Assessment

• DEXA scan or bioimpedance analysis (body fat %)
• Waist circumference, body weight
• Progress photos (front, side, back)
• Bloodwork: IGF-1, fasting glucose, fasting insulin, lipid panel
• Training max assessment (key lifts: squat, deadlift, bench)

Weeks 1-12: Peptide + Training + Nutrition

Peptide Protocol:

• AM Dose (Upon Waking): 150 mcg CJC-1295 + 250 mcg Ipamorelin
  • Inject immediately upon waking (empty stomach from overnight fast)
  • Wait 60 minutes before eating
  • Black coffee/water allowed during fast
• PM Dose (Before Bed): 150 mcg CJC-1295 + 250 mcg Ipamorelin
  • Last meal 3 hours before bed
  • Inject 30-60 minutes before sleep
  • No food after injection

Training Protocol (4x/week):

• Monday/Thursday: Upper body resistance (chest, back, shoulders, arms)
• Tuesday/Friday: Lower body resistance (quads, hamstrings, glutes, calves)
• Wednesday/Saturday: Optional: 30-40 min low-intensity cardio (fasted morning)
• Sunday: Complete rest
• Rep range: 8-12 reps, 3-4 sets per exercise, focus on progressive overload

Nutrition Strategy:

• Caloric Intake: Maintenance or 10-15% deficit (e.g., 2200 kcal if maintenance is 2500)
• Protein: 1.8-2.2 g/kg body weight (prioritize GH/IGF-1 muscle-sparing effect)
• Carbs: Moderate (150-200g/day), timed around training
• Fats: 0.8-1.0 g/kg body weight
• Meal Timing:
  • Post-AM injection (60 min): Protein-rich breakfast (eggs, Greek yogurt, protein shake)
  • Pre-workout: Moderate carbs (oats, fruit)
  • Post-workout: Protein + carbs within 2 hours
  • Dinner: Protein + vegetables, lower carb
  • No food 3 hours before PM injection

Weeks 4, 8, 12: Progress Assessment

• Body weight, waist circumference
• Progress photos
• Subjective: Energy, recovery, sleep quality
• Week 8: Repeat IGF-1, fasting glucose

Expected Results (Realistic):

• Body Fat: -2 to -4% over 12 weeks (e.g., 18% → 14-16%)
• Lean Mass: +1 to +4 lbs (or maintained during deficit)
• Waist: -1 to -2.5 inches
• Strength: Maintained or slight increase despite deficit
• Recovery: Markedly improved (less DOMS, faster return to training)

Weeks 13-16: Off-Cycle

• Stop CJC-1295 and Ipamorelin completely
• Maintain training and nutrition
• Expect: Slight regression in recovery speed, body composition stabilizes or slight rebound

Week 16: Reassess and Decide:

• If results maintained: Consider second 12-week cycle
• If significant regression: Adjust nutrition/training before second cycle
• Long-term strategy: 2-3 cycles per year maximum

Muscle Building and Athletic Performance

Primary Application: Enhancing hypertrophy, strength gains, and athletic performance through GH/IGF-1 anabolic effects.

Mechanism Alignment:

• IGF-1 directly stimulates muscle protein synthesis via mTOR pathway activation
• GH enhances amino acid uptake in muscle tissue
• Improved recovery allows higher training volume and frequency
• Collagen synthesis strengthens tendons/ligaments (supports heavier lifting)
• Enhanced nitrogen retention (anti-catabolic effect)

Target Outcomes:

• Increased lean muscle mass (1-4 lbs over 12 weeks, highly variable)
• Strength gains (5-10% improvement in key lifts)
• Improved training capacity (higher volume tolerance)
• Reduced delayed-onset muscle soreness (DOMS)
• Enhanced muscle fullness and pump

Protocol Recommendation: Aggressive twice-daily protocol (post-workout + bedtime) during muscle-building phase. CJC-1295 WITHOUT DAC 150-200 mcg + Ipamorelin 250-300 mcg per dose. Combine with structured progressive overload training and caloric surplus (200-500 kcal/day above maintenance).

Practical Biohacker Implementation: Hypertrophy Optimization

12-Week Muscle Building Protocol:

Peptide Timing (Critical for Muscle Building):

• Dose 1 (Post-Workout): 150-200 mcg CJC-1295 + 250-300 mcg Ipamorelin
  • Inject 30-60 minutes POST-workout (fasted from pre-workout meal)
  • Captures exercise-induced GH window for synergistic effect
  • Wait 30 minutes, then consume post-workout meal (protein + carbs)
• Dose 2 (Before Bed): 150-200 mcg CJC-1295 + 250-300 mcg Ipamorelin
  • Standard bedtime protocol (see timing above)
  • Aligns with nocturnal GH pulse for maximum 24-hour GH exposure

Training Split (5-6 days/week, high volume):

• Day 1: Chest + Triceps (8-10 sets chest, 6-8 sets triceps)
• Day 2: Back + Biceps (8-10 sets back, 6-8 sets biceps)
• Day 3: Legs (10-12 sets quads, 6-8 sets hamstrings, 4-6 sets calves)
• Day 4: Shoulders + Abs (8-10 sets delts, 4-6 sets abs)
• Day 5: Rest or light cardio
• Day 6: Optional: Weak point focus (arms, calves, etc.)
• Day 7: Complete rest

Nutrition (Muscle Building Surplus):

• Calories: 200-500 above maintenance (aggressive surplus leverages GH nutrient partitioning)
• Protein: 2.0-2.5 g/kg body weight (high protein to maximize IGF-1 anabolic stimulus)
• Carbs: 4-6 g/kg body weight (fuel training volume)
• Fats: 0.8-1.2 g/kg body weight
• Post-Workout (after 30 min wait): 40-50g protein + 60-80g carbs within 60 min of injection
• Pre-Bed: Slow-digesting protein (casein shake or cottage cheese) 2-3 hours before PM injection

Expected Results:

• Lean Mass Gain: 2-6 lbs over 12 weeks (1-1.5 lbs/month realistic)
• Strength: 10-15% increase in compound lifts
• Recovery: Train same muscle group twice weekly due to enhanced recovery
• Note: Gains highly dependent on training age (novices gain more, advanced lifters less)

Recovery Enhancement and Injury Rehabilitation

Primary Application: Accelerating recovery from training, injury, or surgery through GH-mediated tissue repair.

Mechanism Alignment:

• Collagen synthesis (Type I, II, III collagen for tendons, ligaments, cartilage)
• Enhanced protein synthesis in damaged muscle tissue
• Improved wound healing and tissue regeneration
• Anti-inflammatory effects (via IGF-1)
• Cartilage repair and bone remodeling

Target Outcomes:

• Faster recovery between training sessions (reduced DOMS duration)
• Accelerated healing of musculoskeletal injuries (tendinopathy, ligament sprains)
• Improved post-surgical recovery
• Enhanced sleep quality (critical for recovery)
• Reduced chronic joint pain

Protocol Recommendation: CJC-1295 WITHOUT DAC + Ipamorelin + BPC-157 + TB-500 combination. Twice daily dosing during active injury recovery, once daily for general training recovery enhancement. Duration: 8-12 weeks or until injury resolution.

Practical Biohacker Implementation: Injury Recovery Stack

Complete Tissue Repair Protocol:

Peptide Stack (Injury/Post-Surgery Recovery):

Administration:

• AM (Upon Waking): CJC-1295 + Ipamorelin (mixed, subcutaneous abdomen)
  • Wait 15 minutes
  • BPC-157 (subcutaneous, near injury if accessible, or abdomen)
• PM (Before Bed): CJC-1295 + Ipamorelin (mixed, subcutaneous)
  • Wait 15 minutes
  • BPC-157 (subcutaneous, rotate sites)
• TB-500: Monday + Thursday (loading weeks 1-4), then Monday only (maintenance weeks 5-12)

Recovery-Focused Training (Modified During Injury):

• Acute Injury Phase (Weeks 1-2): Complete rest of injured area; gentle ROM exercises
• Rehabilitation Phase (Weeks 3-6): Progressive loading (bodyweight → light resistance)
• Return to Training (Weeks 7-12): Gradual increase to pre-injury training volume
• Peptides enhance healing but DO NOT replace proper rehabilitation protocols

Nutrition for Tissue Repair:

• Protein: 2.0-2.5 g/kg (collagen/amino acid substrate for repair)
• Vitamin C: 500-1000 mg/day (collagen synthesis cofactor)
• Glycine/Proline: Consider collagen peptide supplementation (10-20g/day)
• Omega-3 Fatty Acids: 2-3g/day EPA/DHA (anti-inflammatory)
• Calories: Maintenance or slight surplus (healing is anabolic, requires energy)

Expected Timeline (Example: Patellar Tendinopathy):

• Weeks 1-4: Pain reduction, improved function
• Weeks 4-8: Significant healing, return to modified training
• Weeks 8-12: Near-complete resolution, return to full training
• Note: Timeline varies by injury type/severity; severe injuries may require extended protocols

General Training Recovery (Not Injured):

• Simplify to CJC-1295 + Ipamorelin only (once daily, bedtime)
• Expected benefit: 20-40% reduction in DOMS, faster return to training

Archetype Summary Table

Note: CJC-1295 WITH DAC is generally NOT recommended for goal archetype protocols due to its non-physiological sustained GH pattern. The WITHOUT DAC version's pulsatile release more closely aligns with optimization goals.

---|----------------|-----------|-------------| | CJC-1295 (alone, ambiguous) | Could be either version | Depends | ALWAYS CLARIFY | | CJC-1295 With DAC | Long-acting, albumin-binding | 6-8 days | Once weekly dosing | | CJC-1295 DAC | Same as above | 6-8 days | Once weekly dosing | | CJC-1295 Without DAC | Short-acting, no albumin binding | 30 min | Daily dosing, often with ipamorelin | | CJC-1295 No DAC | Same as above | 30 min | Daily dosing, often with ipamorelin | | Modified GRF (1-29) | Same as CJC-1295 Without DAC | 30 min | Daily dosing, often with ipamorelin | | Mod GRF 1-29 | Same as CJC-1295 Without DAC | 30 min | Daily dosing, often with ipamorelin |

Why This Matters:

• Many suppliers sell "CJC-1295" without specifying which version
• Dosing protocols are completely different for each version
• Using the wrong version or wrong dosing can lead to ineffective treatment or adverse effects
• When purchasing or researching, ALWAYS confirm: With DAC or Without DAC?

2. Mechanism of Action

Both versions of CJC-1295 work through the same fundamental mechanism—stimulation of GHRH receptors—but with different pharmacodynamic profiles due to their pharmacokinetic differences.

2.1 GHRH Receptor Binding

Primary Target: Growth Hormone-Releasing Hormone Receptor (GHRHR)

Receptor Characteristics:

• G protein-coupled receptor (GPCR) with 7 transmembrane domains
• Located on somatotroph cells in the anterior pituitary gland
• Also present in hypothalamic arcuate nucleus (feedback regulation)
• Coupled to Gs proteins (stimulatory G proteins)

Binding Mechanism:

1. CJC-1295 binds to the N-terminal extracellular domain of GHRHR
2. The α-helical structure (residues 6-27) is critical for high-affinity binding
3. Amino acid substitutions (D-Ala², Gln⁸, Ala¹⁵, Leu²⁷) enhance receptor affinity and stability
4. Binding induces conformational change in receptor, activating Gs protein

2.2 Intracellular Signaling Cascade

G Protein Activation:

• GHRHR activates Gs (stimulatory G protein)
• Gs α-subunit dissociates and activates adenylyl cyclase

Second Messenger Generation:

1. Adenylyl Cyclase Activation: Converts ATP to cyclic AMP (cAMP)
2. cAMP Accumulation: Intracellular cAMP levels rise rapidly
3. Protein Kinase A (PKA) Activation: cAMP binds to regulatory subunits of PKA, releasing catalytic subunits

Transcription and Secretion: 4. CREB Phosphorylation: PKA phosphorylates CREB (cAMP Response Element Binding protein) 5. GH Gene Transcription: Phosphorylated CREB binds to CRE (cAMP Response Element) in GH gene promoter 6. GH Synthesis: Increased transcription → increased GH mRNA → increased GH protein synthesis 7. GH Secretion: PKA also triggers fusion of GH-containing secretory vesicles with cell membrane 8. Pulsatile Release: GH released in pulses into bloodstream

2.3 Pharmacodynamic Differences: With DAC vs Without DAC

CJC-1295 WITH DAC:

Pharmacodynamic Profile:

• Duration of GH Elevation: 6+ days after single injection
• Pattern: Sustained, continuous GH elevation (not pulsatile)
• IGF-1 Response: Sustained elevation for 9-11 days
• Magnitude: 2- to 10-fold increase in GH; 1.5- to 3-fold increase in IGF-1

Clinical Implications:

• Mimics continuous GH infusion (similar to exogenous GH therapy)
• Advantages: Convenient (once weekly dosing)
• Disadvantages: Non-physiological pattern (GH normally secreted in pulses); may increase side effect risk; if side effects occur, peptide remains active for days

CJC-1295 WITHOUT DAC (Mod GRF 1-29):

Pharmacodynamic Profile:

• Duration of GH Elevation: 2-4 hours after injection
• Pattern: Pulsatile (mimics natural GH secretion)
• IGF-1 Response: Gradual increase with repeated dosing
• Magnitude: Moderate GH pulse (similar to natural secretion)

Clinical Implications:

• Mimics endogenous GHRH (physiological)
• Advantages: Preserves natural GH pulsatility; shorter duration means faster recovery if side effects occur
• Disadvantages: Requires daily (or twice daily) dosing; less convenient

2.4 Synergy with Growth Hormone Secretagogues (GHRPs)

Complementary Mechanisms:

CJC-1295 (GHRH analog):

• Acts via GHRH receptors → Gs → cAMP → PKA

Ipamorelin/GHRP-6 (Ghrelin mimetics):

• Act via GHS-R1a (ghrelin receptors) → Gq → IP₃/DAG → Ca²⁺/PKC

Synergistic Effects: When CJC-1295 (especially WITHOUT DAC) is combined with a GHRP like ipamorelin:

• Two pathways (cAMP and calcium) converge on somatotrophs
• Amplified GH Release: 3-5 fold greater than either alone (true synergy, not just additive)
• Enhanced Pulsatility: More closely mimics natural GH secretion
• Clinical Popularity: CJC-1295 Without DAC + Ipamorelin is one of the most popular peptide combinations

Why NOT Combine CJC-1295 WITH DAC + Ipamorelin for Same-Day Dosing:

• WITH DAC causes sustained, non-pulsatile GH elevation
• Ipamorelin produces short pulses
• Combining them creates an unnatural pattern (sustained baseline + pulsatile spikes)
• Most practitioners avoid this combination for daily use
• If using WITH DAC, it's typically dosed separately (e.g., weekly) without concurrent GHRP dosing

2.5 Downstream Effects of Growth Hormone

Hepatic IGF-1 Production:

• GH binds to GH receptors in liver
• Stimulates IGF-1 (insulin-like growth factor-1) synthesis and secretion
• IGF-1 mediates most anabolic effects of GH

Metabolic Effects:

• Lipolysis: Increases fat breakdown (anti-obesity effect)
• Protein Synthesis: Enhances muscle protein synthesis (anabolic)
• Glucose Metabolism: Mild insulin antagonism (raises blood glucose)
• Bone Remodeling: Stimulates osteoblasts (increases bone density)

Tissue Repair and Regeneration:

• Collagen synthesis (skin, tendons, ligaments)
• Cartilage repair
• Immune function support

3. Dosing Protocols and Administration

3.1 CJC-1295 WITH DAC Dosing

Infrequent Dosing (Long Half-Life):

Standard Protocol:

• Dose: 1-2 mg per injection
• Frequency: Once per week
• Route: Subcutaneous injection
• Duration: 8-12 weeks, followed by 4-week break

Body Weight-Based Dosing (Based on Clinical Trials):

• Research Dose: 30-60 mcg/kg weekly
• Example for 80 kg (176 lbs) individual:
  • Low dose: 80 kg × 30 mcg/kg = 2,400 mcg (2.4 mg)
  • High dose: 80 kg × 60 mcg/kg = 4,800 mcg (4.8 mg)
• Most Common: 2 mg once weekly

Alternative Biweekly Protocol:

• Dose: 2-3 mg per injection
• Frequency: Every 2 weeks (14 days)
• Rationale: Some practitioners use biweekly dosing to further reduce injection frequency, though this is less common

Timing:

• Can be administered at any time of day (due to long half-life, timing is less critical)
• Many prefer evening to align with natural nocturnal GH pulse (though effect is sustained, not pulsatile)

3.2 CJC-1295 WITHOUT DAC Dosing (Mod GRF 1-29)

Frequent Dosing (Short Half-Life):

Standard Protocol:

• Dose: 100-200 mcg per injection
• Frequency: 1-3 times per day
• Route: Subcutaneous injection
• Duration: 8-12 weeks, followed by 4-week break

Specific Timing Protocols:

Once Daily (Bedtime):

• Dose: 100-200 mcg
• Timing: 30-60 minutes before sleep
• Best For: Anti-aging, general wellness, convenience

Twice Daily (AM + PM):

• Dose: 100-200 mcg per injection
• Timing: Upon waking (fasted) + before bed
• Best For: Body composition goals, enhanced GH exposure

Three Times Daily (Aggressive):

• Dose: 100 mcg per injection
• Timing: Upon waking, post-workout, before bed
• Best For: Bodybuilding, maximum GH optimization
• Note: Inconvenient; most users find twice daily sufficient

Body Weight-Based Dosing:

• Research Dose: 10 mcg/kg per day (can be split into multiple doses)
• Example for 80 kg individual: 80 kg × 10 mcg/kg = 800 mcg total per day
  • Split into 2 doses: 400 mcg AM + 400 mcg PM
  • Split into 3 doses: ~270 mcg each
• Practical Note: Most users stick to 100-200 mcg per dose regardless of weight

3.3 Combination Dosing: CJC-1295 Without DAC + Ipamorelin

Most Popular Peptide Stack:

Standard Combination:

• CJC-1295 (No DAC): 100-200 mcg
• Ipamorelin: 200-300 mcg
• Administration: Mixed in same syringe, injected together
• Frequency: Once daily (bedtime) or twice daily (AM + PM)
• Duration: 8-12 weeks, then 4-week break

Dosing by Body Weight (Combination):

Timing for Combination:

• Bedtime (Most Common): Aligns with natural nocturnal GH pulse; convenient
• AM + PM (Advanced): Maximizes pulsatile GH pattern

Fasting Requirement (CRITICAL):

• Before Injection: Fast for 90-120 minutes (no food)
• After Injection: Fast for 30-60 minutes
• Reason: Elevated glucose and insulin blunt GH response

3.4 Practical Injection Administration

Subcutaneous Injection Sites:

• Abdomen: 2 inches lateral to navel (most common)
• Outer Thigh: Vastus lateralis
• Upper Arm: Deltoid (requires assistance)

Technique:

1. Clean site with alcohol swab, allow to dry
2. Pinch skin to create fold
3. Insert needle at 45-90° angle (depending on needle length)
4. Inject slowly (5-10 seconds)
5. Withdraw needle, apply gentle pressure
6. Rotate sites to prevent lipohypertrophy or lipoatrophy

Mixing CJC-1295 + Ipamorelin:

• Draw prescribed dose of each peptide into same syringe
• Gently mix (do not shake vigorously)
• Inject immediately

3.5 Age-Stratified Dosing Guidelines

Age significantly impacts GH secretion capacity, pituitary responsiveness, and risk tolerance. The following age-stratified recommendations apply to CJC-1295 WITHOUT DAC in combination with Ipamorelin (the preferred protocol for most users).

Rationale for Age-Based Dosing:

• Younger individuals (<40) have higher baseline GH secretion and more responsive pituitary
• Middle-aged individuals (40-55) experience progressive somatopause (declining GH)
• Older individuals (55+) have significantly reduced GH secretion but also increased risk factors
• Goal is optimization within physiological range, not supraphysiological elevation

GH Decline by Age (Understanding the Context):

This progressive decline underlies the age-stratified approach—older individuals have greater deficit but also require more conservative dosing due to increased comorbidity risk.

Under 40 Years: Conservative Protocol

Typical Profile:

• Higher baseline GH/IGF-1 levels
• More responsive somatotrophs
• Lower risk profile
• Often seeking performance/recovery optimization rather than replacement

Recommended Protocol:

• CJC-1295 (No DAC): 100 mcg nightly
• Ipamorelin: 100-200 mcg nightly
• Frequency: Once daily, 30-60 minutes before sleep
• Duration: 8-12 weeks on, 4 weeks off

Rationale:

• Lower doses often sufficient due to preserved pituitary function
• Focus on amplifying natural GH pulse rather than replacing
• Conservative approach minimizes risk in lower-risk population
• Twice daily dosing rarely necessary unless aggressive body composition goals

Monitoring:

• Baseline IGF-1 before initiating
• Reassess at 6-8 weeks
• Target: Upper-normal range for age (not supraphysiological)

Ages 40-55 Years: Standard Protocol

Typical Profile:

• Progressive decline in GH secretion (somatopause onset)
• Moderate reduction in pituitary responsiveness
• May have emerging metabolic risk factors
• Often seeking anti-aging and body composition benefits

Recommended Protocol:

• CJC-1295 (No DAC): 100-150 mcg nightly
• Ipamorelin: 200-300 mcg nightly
• Frequency: Once daily (bedtime) or twice daily (AM + PM) for aggressive goals
• Duration: 8-12 weeks on, 4 weeks off

Rationale:

• Moderate dose increase compensates for reduced pituitary responsiveness
• Standard combination ratio (CJC-1295:Ipamorelin approximately 1:2)
• Twice daily option for those with body composition or recovery goals
• Represents most common dosing range in clinical anti-aging practice

Monitoring:

• Baseline IGF-1, fasting glucose, HbA1c
• Reassess at 6-8 weeks
• Consider thyroid function (TSH, free T4)
• Target: Age-appropriate upper tertile for IGF-1

Ages 55+ Years: Conservative Protocol with Enhanced Monitoring

Typical Profile:

• Significant GH decline (may be 50%+ below youthful levels)
• Reduced pituitary responsiveness
• Higher prevalence of comorbidities (CV disease, diabetes, cancer history)
• Increased sensitivity to GH effects (both benefits and side effects)
• Anti-aging and quality of life primary goals

Recommended Protocol:

• CJC-1295 (No DAC): 100 mcg nightly
• Ipamorelin: 100-200 mcg nightly
• Frequency: Once daily, 30-60 minutes before sleep
• Duration: 8-12 weeks on, 4-6 weeks off

Rationale:

• Conservative dosing despite greater GH deficit
• Older individuals often more sensitive to GH effects
• Higher risk profile necessitates caution over aggressive optimization
• Focus on quality of life improvements rather than maximum GH stimulation
• Extended off-cycle periods (4-6 weeks) for safety

Enhanced Monitoring Requirements:

• Comprehensive baseline: IGF-1, fasting glucose, HbA1c, lipid panel, PSA (men), mammogram (women)
• Cardiovascular assessment if risk factors present
• More frequent monitoring: Every 4-6 weeks initially
• Annual comprehensive assessment for long-term users
• Target: Conservative IGF-1 target (mid-to-upper normal for age)

Special Considerations for 55+:

• Screen for contraindications (cancer history, CV disease, diabetes)
• Start at lower end of dose range and titrate slowly
• Longer off-cycle periods may reduce long-term risk
• If side effects occur, discontinue and reassess
• Consider consultation with endocrinologist for complex cases

Age-Stratified Dosing Summary Table

Important Notes:

• All doses assume CJC-1295 WITHOUT DAC (Mod GRF 1-29)
• Individual variation exists; some may require dose adjustment
• Presence of comorbidities may necessitate further dose reduction
• Supraphysiological IGF-1 elevation should be avoided at any age
• Clinical supervision recommended, especially for 55+ population

3.6 Sex-Specific Considerations and Dosing

Biological sex significantly influences GH physiology, response to CJC-1295, and risk profile. The following section provides evidence-based guidance for sex-specific optimization.

Physiological Sex Differences in GH Secretion

Male GH Secretion Pattern:

• Pulsatile Pattern: Fewer, higher-amplitude GH pulses (4-8 major pulses per 24 hours)
• Nocturnal Dominance: 60-70% of daily GH secreted during deep sleep
• Testosterone Influence: Androgens potentiate GH secretion and IGF-1 production
• Age Decline: Progressive decline begins ~25-30 years, accelerates after 40

Female GH Secretion Pattern:

• More Frequent Pulses: Greater pulse frequency but lower amplitude (8-12 pulses per 24 hours)
• Daytime Secretion: More distributed throughout 24-hour period (less nocturnal dominance)
• Estrogen Influence: Estrogen increases GH secretion but DECREASES hepatic IGF-1 production (paradox)
• Menstrual Cycle Variation: GH secretion varies across cycle (highest mid-luteal phase)
• Age Decline: More gradual decline; dramatic drop at menopause

Clinical Implication: Women typically have higher GH secretion but lower IGF-1 levels compared to men—this is physiologically normal and reflects estrogen's hepatic effect.

Sex-Specific Dosing Recommendations

Males: Standard Protocol

Key Considerations for Males:

• Testosterone Status Matters: Hypogonadal men may have blunted CJC-1295 response; optimize testosterone first
• IGF-1 Response: Expect robust IGF-1 increase (25-50% from baseline)
• Muscle Building Goals: Males respond well to twice-daily dosing for body composition
• Prostate Monitoring: PSA testing critical for men >40 (GH/IGF-1 may affect prostate)

Females: Adjusted Protocol

Key Considerations for Females:

• Estrogen Status Matters: Premenopausal women often need LOWER doses due to higher endogenous GH
• IGF-1 Interpretation: Lower IGF-1 despite higher GH is NORMAL in women (especially if taking oral estrogen)
• Oral vs Transdermal Estrogen: Oral estrogen SEVERELY blunts hepatic IGF-1 production; transdermal less affected
• Menstrual Cycle Timing: Some practitioners time CJC-1295 cycles to follicular phase (days 1-14)
• Menopause: Postmenopausal women can use standard male dosing protocols

Estrogen-Related IGF-1 Considerations (Critical for Women)

The Estrogen-IGF-1 Paradox:

Women on oral estrogen (hormone replacement therapy or birth control) experience:

• Increased GH secretion (estrogen stimulates pituitary)
• Decreased hepatic IGF-1 production (first-pass hepatic effect)
• Net result: Normal or low IGF-1 despite adequate GH

Clinical Management:

Practical Recommendation for Women on Oral Estrogen:

• If considering CJC-1295, discuss with physician about switching to transdermal estrogen patch
• Transdermal bypasses hepatic first-pass effect, allowing normal IGF-1 response
• If oral estrogen must continue, IGF-1 may remain lower despite effective GH elevation—use clinical response (energy, recovery, body composition) as primary endpoints

Pregnancy and Breastfeeding

ABSOLUTE CONTRAINDICATION: CJC-1295 (both versions) should NOT be used during:

• Pregnancy (any trimester)
• Breastfeeding
• Actively trying to conceive

Rationale:

• No safety data in pregnant or breastfeeding women
• GH/IGF-1 effects on fetal development unknown
• Theoretical risk of abnormal fetal growth patterns

Recommendation: Women of childbearing potential should use reliable contraception during CJC-1295 cycles and discontinue at least 4 weeks before attempting conception.

Menstrual Cycle Considerations

GH Secretion Across Menstrual Cycle:

• Follicular Phase (Days 1-14): Lower GH amplitude; rising estrogen
• Ovulation (Day 14): GH pulse amplitude increases
• Luteal Phase (Days 15-28): Highest GH secretion (progesterone + estrogen)
• Menstruation (Days 1-5): Hormone withdrawal; GH secretion normalizes

Protocol Timing Options:

Clinical Recommendation: Most practitioners recommend continuous daily dosing for simplicity and steady IGF-1 levels. Cycle-specific timing lacks clinical evidence and complicates compliance.

Sex-Specific Side Effects

Males:

• Gynecomastia Risk: Rare, but GH can increase aromatase activity (testosterone → estrogen conversion)
• Fluid Retention: Men more prone to edema/water retention (especially hands, feet)
• Carpal Tunnel: Higher incidence in males due to larger wrist anatomy + GH-induced swelling
• Prostate Concerns: Theoretical prostate growth risk (PSA monitoring essential)

Females:

• Breast Tenderness: More common in premenopausal women (GH effect on breast tissue)
• Menstrual Changes: Rare reports of cycle irregularity (likely estrogen-mediated)
• Water Retention: Less common than in males
• Headache: Slightly higher incidence in women (possible hormonal interaction)

Hormone Therapy Interactions

Males on Testosterone Replacement Therapy (TRT):

• Synergistic Effects: TRT + CJC-1295 often produce superior body composition results
• Enhanced IGF-1 Response: Testosterone amplifies hepatic IGF-1 production
• Increased Monitoring: More frequent labs (testosterone, estradiol, PSA, IGF-1)
• Aromatization Risk: Higher estradiol from combined therapy may require aromatase inhibitor

Females on Hormone Replacement Therapy (HRT):

• Oral Estrogen: Significantly blunts IGF-1 response (see above)
• Transdermal Estrogen: Minimal effect on IGF-1 response
• Progesterone: May enhance GH secretion in luteal phase
• Combined HRT + CJC-1295: Can be safely combined if using transdermal estrogen

Sex-Specific Monitoring

Males:

• Baseline Required: IGF-1, testosterone, estradiol, PSA, fasting glucose, lipids
• Follow-Up (6-8 weeks): IGF-1, PSA (critical in >40), fasting glucose
• Red Flag: PSA increase >0.5 ng/mL from baseline warrants urologic evaluation

Females:

• Baseline Required: IGF-1, estradiol, fasting glucose, lipids, pregnancy test (if childbearing age)
• Follow-Up (6-8 weeks): IGF-1, fasting glucose
• Estrogen Status Documentation: Record whether using oral vs transdermal estrogen (affects IGF-1 interpretation)
• Red Flag: New menstrual irregularity warrants gynecologic evaluation

Sex-Specific Summary Table

4. Clinical Evidence and Research

4.1 Landmark Clinical Trial: CJC-1295 WITH DAC (2006)

Study: "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults" (Teichman et al., 2006)

Design:

• Randomized, double-blind, placebo-controlled trial
• Participants: Healthy adult volunteers
• Intervention: Single subcutaneous injection of CJC-1295 (WITH DAC) at doses of 30 or 60 mcg/kg
• Primary Endpoints: Plasma GH and IGF-1 levels over time
• Duration: Follow-up for 28 days post-injection

Results:

Growth Hormone Response:

• 2- to 10-fold increase in mean plasma GH concentrations
• GH remained elevated for 6+ days after single injection
• Dose-dependent response (higher dose = higher GH)

IGF-1 Response:

• 1.5- to 3-fold increase in mean plasma IGF-1 concentrations
• IGF-1 remained elevated for 9-11 days
• With multiple doses, IGF-1 levels remained elevated for up to 28 days

Safety:

• CJC-1295 was "safe and relatively well tolerated"
• No serious adverse reactions reported
• Doses of 30 or 60 mcg/kg were particularly well tolerated

Pharmacokinetics:

• Estimated half-life: 5.8-8.1 days
• Clearance was very slow due to DAC-mediated albumin binding

Conclusion: CJC-1295 WITH DAC produces sustained, dose-dependent elevations in GH and IGF-1, demonstrating proof-of-concept for long-acting GHRH therapy.

4.2 Phase II Trial: HIV-Associated Lipodystrophy

Study: Multicenter Phase II trial in HIV-infected patients with visceral obesity

Background:

• HIV patients on antiretroviral therapy often develop abnormal fat distribution (central adiposity)
• GH has lipolytic effects and may reduce visceral fat

Design:

• CJC-1295 administered for 12 weeks
• Assessed efficacy, pharmacokinetics, safety, and tolerability

Status:

• Trial results not fully published
• Development was discontinued following a subject death during trials

Important Note: The subject death was not conclusively linked to CJC-1295, but it led to termination of clinical development by the sponsor. The cause of death remains unclear, and it's unknown whether CJC-1295 was contributory.

4.3 Discontinuation of Clinical Development

Why CJC-1295 WITH DAC Development Stopped:

1. Subject Death: Occurred during Phase II trial (details not publicly disclosed)
2. Sponsor Decision: Manufacturer (Helsinn Therapeutics) discontinued development
3. Regulatory Caution: FDA never approved CJC-1295 for any indication
4. Market Shift: Development resources redirected to other compounds

Current Status:

• CJC-1295 WITH DAC remains an investigational compound
• No FDA-approved formulation exists
• Available only through research chemical suppliers and compounding pharmacies

4.4 CJC-1295 WITHOUT DAC Research

Limited Clinical Trial Data:

• CJC-1295 WITHOUT DAC (Mod GRF 1-29) has not been evaluated in large clinical trials
• Most evidence is extrapolated from:
  • Pharmacology of modified GHRH analogs
  • Anecdotal reports from peptide users
  • Small case series from anti-aging clinics

Mechanistic Studies:

• Demonstrates effective GH stimulation via GHRH receptors
• Short half-life confirmed (~30 minutes)
• Synergy with GHRPs (ipamorelin, GHRP-6) documented in preclinical models

Safety Profile:

• Appears well-tolerated based on limited data
• No reported deaths or serious adverse events linked specifically to WITHOUT DAC version
• Shorter half-life theoretically reduces risk compared to WITH DAC

4.5 Evidence Quality Assessment

4.6 Research Gaps and Needs

Critical Unanswered Questions:

1. Long-Term Safety: No studies beyond 12 weeks; unknown risks of extended use
2. Cancer Risk: GH/IGF-1 promote cell proliferation; long-term cancer risk unknown
3. Cardiovascular Outcomes: FDA warns of CV risks; need rigorous safety data
4. Efficacy in Healthy Adults: Rigorous RCTs needed for body composition, strength, performance
5. Optimal Dosing: No consensus on ideal dose by age, sex, or baseline GH status
6. Comparative Effectiveness: Head-to-head trials vs other GH secretagogues, rhGH, or placebo

5. Safety Profile and Adverse Effects

5.1 Common Side Effects (Both Versions)

Injection Site Reactions:

• Incidence: ~10-20% of users
• Symptoms: Redness, swelling, pain, itching
• Duration: Typically 24-48 hours
• Management: Rotate injection sites, proper technique

Headaches:

• Incidence: ~10-15% (reported in clinical trials)
• Severity: Mild to moderate
• Timing: Often within first few doses
• Resolution: Usually subsides with continued use

Nausea:

• Incidence: ~5-10%
• Character: Mild queasiness
• Management: Inject before sleep (less noticeable)

Vertigo/Dizziness:

• Incidence: ~5%
• Character: Lightheadedness
• Management: Adequate hydration, avoid rapid position changes

Flu-Like Symptoms:

• Incidence: Rare (~2-5%)
• Symptoms: Fatigue, mild fever, body aches
• Duration: Transient (1-2 days)

Mood Swings:

• Incidence: Uncommon (<5%)
• Character: Irritability, mood lability
• Mechanism: GH/IGF-1 effects on neurotransmitters

Increased Body Temperature:

• Incidence: Uncommon
• Character: Mild hyperthermia
• Mechanism: GH's thermogenic effects

5.2 Serious Adverse Events and FDA Warnings

FDA Safety Concerns (2024 Briefing Documents):

1. Cardiovascular Risks:

• Warning: "Increased heart rate and systemic vasodilatory reaction"
• Manifestations: Flushing, warmth, transient hypotension
• Concern: Could exacerbate underlying cardiovascular disease
• Mechanism: GH affects vascular tone and cardiac output

2. Immunogenicity:

• Warning: Risk of allergic reactions, including anaphylaxis
• Mechanism: CJC-1295 is a modified peptide; immune system may recognize as foreign
• Symptoms: Hives, urticaria, facial swelling, difficulty breathing, anaphylactic shock
• Incidence: Very rare, but potentially life-threatening
• Action: Immediate discontinuation if allergic reaction occurs; seek emergency care

3. Subject Death in Clinical Trials:

• One death occurred during Phase II trial (details not publicly disclosed)
• Not conclusively linked to CJC-1295, but raised safety concerns
• Led to discontinuation of clinical development

5.3 Version-Specific Safety Concerns

CJC-1295 WITH DAC (Unique Risks):

1. Non-Physiological GH Pattern:

• Sustained elevation (not pulsatile) is unnatural
• Prolonged GH exposure may increase risk of:
  • Glucose intolerance
  • Acromegaly-like effects (if used long-term at high doses)
  • Fluid retention

2. Prolonged Half-Life (6-8 days):

• Problem: If side effects occur, peptide remains active for days
• Cannot "turn off" effect quickly
• Difficulty titrating dose

3. Risk of Receptor Desensitization:

• Continuous GHRH receptor stimulation may lead to downregulation
• Diminishing returns over time

CJC-1295 WITHOUT DAC (Mod GRF 1-29):

1. Requires Frequent Dosing:

• Daily or twice daily injections increase injection site reaction risk
• Inconvenience may reduce compliance

2. Less Studied:

• No large clinical trials specifically for WITHOUT DAC version
• Safety profile extrapolated from related peptides

5.4 Contraindications

Absolute Contraindications (DO NOT USE):

1. Active Cancer or Malignancy:

   • GH and IGF-1 promote cell proliferation
   • Could theoretically accelerate tumor growth
   • Avoid in any active cancer

2. History of Cancer:

   • Generally avoid within 5 years of remission
   • Consult oncologist for individual risk assessment

3. Critical Illness:

   • ICU patients or acute critical illness
   • GH therapy associated with increased mortality in critically ill

4. Known Allergy to CJC-1295 or Components:

   • Risk of anaphylaxis

Relative Contraindications (Use with Caution/Medical Supervision):

1. Cardiovascular Disease:

   • FDA warns of increased heart rate and vasodilatory effects
   • Monitor closely if history of heart disease, hypertension, or arrhythmias

2. Diabetes Mellitus:

   • GH antagonizes insulin (raises blood glucose)
   • Requires close glucose monitoring
   • May need adjustment of antidiabetic medications

3. Diabetic Retinopathy:

   • GH can worsen proliferative retinopathy
   • Ophthalmologic evaluation and monitoring recommended

4. Pregnancy and Breastfeeding:

   • No safety data
   • Avoid unless benefit clearly outweighs risk

5. Hypothyroidism:

   • GH can affect thyroid hormone metabolism
   • Optimize thyroid replacement before starting
   • Monitor thyroid function during treatment

6. Sleep Apnea:

   • GH may exacerbate obstructive sleep apnea
   • Treat sleep apnea before initiating CJC-1295

7. Pediatric Use (<18 years):

   • No safety data in children
   • Unknown effects on growth and development
   • Not recommended

5.5 Drug Interactions

Medications That May Affect CJC-1295 Efficacy:

1. Glucocorticoids (Corticosteroids):

   • Suppress GH secretion
   • May reduce effectiveness

2. Somatostatin Analogs:

   • Octreotide, lanreotide
   • Directly inhibit GH release
   • CONTRAINDICATED with CJC-1295 - Direct antagonism at receptor level

3. Insulin and Oral Hypoglycemics:

   • GH antagonizes insulin
   • May require adjustment of diabetes medications

4. Thyroid Hormones:

   • GH increases thyroid hormone metabolism
   • May need increased levothyroxine dose

Medications Requiring Monitoring:

• Estrogen (Oral): May reduce IGF-1 response (transdermal less affected)
• Testosterone: Synergistic anabolic effects; monitor closely
• Antihypertensives: GH may affect blood pressure; monitor

5.6 Expanded Drug Interaction Details

This section provides detailed guidance on critical drug interactions relevant to CJC-1295 use in clinical practice.

Diabetes Medications: Monitor Glucose Closely

Interaction Type: Pharmacodynamic antagonism

Mechanism:

• Growth hormone directly antagonizes insulin action at the receptor level
• GH promotes hepatic gluconeogenesis (increased glucose production)
• GH reduces peripheral glucose uptake in muscle and adipose tissue
• Net effect: Elevation of blood glucose (diabetogenic effect)

Affected Medications:

• Insulin (all types): Rapid-acting, short-acting, intermediate, long-acting
• Sulfonylureas: Glipizide, glyburide, glimepiride
• Meglitinides: Repaglinide, nateglinide
• Metformin: Less affected (works via different mechanism)
• SGLT2 Inhibitors: Empagliflozin, dapagliflozin, canagliflozin
• GLP-1 Agonists: Semaglutide, liraglutide, tirzepatide

Clinical Management:

Monitoring Protocol for Diabetic Patients:

1. Baseline: Fasting glucose, HbA1c before initiating CJC-1295
2. Week 2-4: Daily fasting glucose checks (self-monitoring)
3. Week 6-8: Repeat fasting glucose and HbA1c
4. Ongoing: Quarterly HbA1c if continuing CJC-1295

Dose Adjustments:

• Insulin users may require 10-20% dose increase
• Sulfonylurea users: Monitor for hypoglycemia if insulin resistance improves
• Inform prescribing physician of CJC-1295 use for coordinated diabetes management

Somatostatin and Somatostatin Analogs: CONTRAINDICATED

Interaction Type: Direct pharmacological antagonism

Mechanism:

• Somatostatin (also called GHIH - Growth Hormone Inhibiting Hormone) directly inhibits GH release from pituitary
• CJC-1295 (GHRH analog) stimulates GH release
• These are opposing physiological regulators - using both simultaneously creates pharmacological contradiction

Affected Medications:

• Octreotide (Sandostatin): Used for acromegaly, carcinoid tumors, variceal bleeding
• Lanreotide (Somatuline): Used for acromegaly, neuroendocrine tumors
• Pasireotide (Signifor): Used for Cushing's disease, acromegaly

Clinical Implications:

• DO NOT combine CJC-1295 with any somatostatin analog
• Somatostatin analogs will completely negate CJC-1295 effects
• If patient requires somatostatin analog for medical condition, CJC-1295 is not appropriate

Exception:

• If somatostatin analog is discontinued, a washout period of 2-4 weeks (depending on formulation half-life) should elapse before initiating CJC-1295

Ipamorelin: Synergistic - Classic Combination

Interaction Type: Pharmacodynamic synergy (beneficial)

Mechanism:

• CJC-1295 acts via GHRH receptors (Gs-coupled, cAMP pathway)
• Ipamorelin acts via ghrelin/GHS-R1a receptors (Gq-coupled, calcium/PKC pathway)
• Two distinct signaling pathways converge on somatotrophs
• Result: Amplified GH release (3-5 fold greater than either peptide alone)

Why This Combination Works:

1. Complementary Mechanisms: Different receptor targets, additive effects
2. Preserved Pulsatility: Both peptides produce pulsatile (not sustained) GH release
3. Safety Profile: Ipamorelin is considered one of the safest GHRPs (minimal cortisol/prolactin elevation)
4. Convenience: Can be mixed in same syringe, administered together

Recommended Combination Protocol:

Administration:

• Draw both peptides into same insulin syringe
• Inject subcutaneously (abdomen preferred)
• Timing: 30-60 minutes before sleep (for single daily dose)
• Fasting: 90-120 minutes before, 30-60 minutes after injection

Clinical Note: The CJC-1295 (No DAC) + Ipamorelin combination is the most widely used peptide stack in anti-aging and wellness medicine. The synergy is well-documented and the combination is considered first-line for GH optimization protocols.

CJC-1295 WITH DAC vs WITHOUT DAC: Critical Distinction

Interaction Type: Not a drug interaction per se, but critical protocol consideration

Key Differences:

WITH DAC Version:

• The DAC (Drug Affinity Complex) is a maleimide group that binds to serum albumin
• Creates sustained-release effect (6-8 day half-life)
• Produces non-physiological, continuous GH elevation
• NOT recommended for combination with ipamorelin (creates conflicting GH patterns)
• Clinical development discontinued following subject death in trials
• Generally not preferred for goal archetype protocols

WITHOUT DAC Version (Mod GRF 1-29):

• Short half-life (30 minutes) requires daily dosing
• Produces physiological pulsatile GH release
• Ideal for combination with ipamorelin (synergistic)
• More closely mimics natural GHRH action
• Preferred version for most clinical applications

Clinical Recommendation: When "CJC-1295" is mentioned without specification, always clarify which version is being used. Dosing, timing, and combination protocols are completely different between the two versions.

Other Peptide Interactions

Synergistic Combinations (Beneficial):

Avoid Combining:

5.7 Long-Term Safety Considerations

Theoretical Risks (Lack of Long-Term Human Data):

1. Cancer Risk:

• GH and IGF-1 promote cell proliferation
• Epidemiological studies link high IGF-1 to increased cancer risk (prostate, breast, colorectal)
• Unknown: Cancer risk with CJC-1295 in long-term users (>5 years)

2. Cardiovascular Effects:

• Acromegaly (GH excess) associated with cardiomyopathy, hypertension
• Physiological GH elevation (CJC-1295-induced) may be safer, but unknown

3. Glucose Intolerance:

• Chronic GH elevation can impair insulin sensitivity
• Risk of type 2 diabetes with long-term use?

Recommendation: Periodic monitoring for long-term users (>6 months):

• IGF-1 levels (maintain in mid-normal range for age)
• Fasting glucose and HbA1c
• Thyroid function (TSH, free T4)
• Lipid panel
• Blood pressure
• Clinical assessment for signs of acromegaly

5.8 Bloodwork Monitoring Protocol

Proper laboratory monitoring is essential for safe and effective CJC-1295 use. This section provides comprehensive guidance on when, what, and how to monitor.

Baseline Testing (Before Initiating CJC-1295)

Required Labs:

Recommended Additional Labs (Based on Risk Profile):

Follow-Up Testing Schedule

Week 6-8: First Follow-Up Panel

Month 3: Comprehensive Assessment

All baseline labs plus:

• Symptom assessment (energy, sleep, recovery)
• Side effect review
• Dose adjustment if needed

Every 3-6 Months (Ongoing Users):

IGF-1 Target Ranges

Understanding IGF-1 Goals:

IGF-1 is the primary biomarker for assessing GH/CJC-1295 response. The goal is to optimize IGF-1 to the age-appropriate upper tertile - NOT to achieve supraphysiological levels.

Age-Appropriate IGF-1 Reference Ranges (ng/mL):

Note: Reference ranges vary by laboratory. Use the reference range provided by your specific lab.

Interpreting IGF-1 Results:

Why NOT Supraphysiological?

• Epidemiological studies associate high IGF-1 with increased cancer risk (prostate, breast, colorectal)
• Supraphysiological GH/IGF-1 can cause acromegaly-like side effects
• Goal is optimization, not maximization
• Risk-benefit ratio becomes unfavorable at supraphysiological levels

Fasting Glucose and Insulin Monitoring

Why Monitor Glucose?

• GH directly antagonizes insulin action
• GH promotes hepatic glucose production
• Long-term GH exposure can impair glucose tolerance
• Early detection prevents progression to diabetes

Fasting Glucose Interpretation:

Fasting Insulin and HOMA-IR:

HOMA-IR Calculation:

HOMA-IR = (Fasting Insulin x Fasting Glucose) / 405

Thyroid Monitoring

Why Monitor Thyroid?

• GH increases peripheral conversion of T4 to T3
• GH may unmask subclinical hypothyroidism
• Thyroid optimization is important for CJC-1295 efficacy
• Hypothyroid patients may have blunted GH response

Thyroid Panel Interpretation:

Clinical Note: Patients on levothyroxine may require dose adjustment during CJC-1295 therapy as GH can affect thyroid hormone metabolism.

Monitoring Schedule Summary Table

Red Flags Requiring Immediate Action

Stop CJC-1295 and Seek Medical Evaluation If:

5.9 Marker-Based Dosing: Titrating CJC-1295 to Biomarkers

Rather than using fixed dosing protocols, advanced practitioners implement marker-based dosing—adjusting CJC-1295 and Ipamorelin doses based on IGF-1 response, clinical symptoms, and metabolic markers. This individualized approach optimizes efficacy while minimizing risk.

The Marker-Based Dosing Philosophy

Traditional Fixed-Dose Approach:

• All patients receive same dose (e.g., 100 mcg CJC-1295 + 200 mcg Ipamorelin)
• IGF-1 response varies widely (some achieve target, others don't)
• No individualization for age, sex, body composition, or baseline GH status

Marker-Based Titration Approach:

• Start with conservative dose
• Measure IGF-1 at 6-8 weeks
• Titrate dose UP or DOWN based on IGF-1 response relative to age-appropriate target
• Adjust based on metabolic markers (glucose, insulin sensitivity)
• Use clinical response as secondary endpoint

Why This Matters:

• Inter-individual variability in CJC-1295 response is HIGH (~3-fold range)
• Same dose produces very different IGF-1 levels in different patients
• Supraphysiological IGF-1 increases cancer/metabolic risk
• Suboptimal IGF-1 means wasted peptide and minimal benefit

IGF-1-Guided Titration Protocol

Step 1: Establish Baseline and Target

1. Measure Baseline IGF-1 before starting CJC-1295
2. Determine Age-Appropriate Target (upper tertile for age)
3. Calculate Target IGF-1 Range

Example for 45-year-old male:

• Reference range: 94-269 ng/mL
• Upper tertile: 211-269 ng/mL
• Target IGF-1: 230-260 ng/mL (conservative within upper tertile)

Step 2: Start with Conservative Dose

Rationale: Start low to assess individual responsiveness.

Step 3: Measure IGF-1 at 6-8 Weeks

Timing is critical:

• Allow 6-8 weeks for IGF-1 to plateau
• Earlier testing (Week 2-4) shows incomplete response
• Later testing (>12 weeks) delays necessary adjustments

Step 4: Titrate Based on IGF-1 Response

Dose Adjustment Examples:

Example 1: Suboptimal Response

• Patient: 42-year-old male
• Baseline IGF-1: 150 ng/mL (low-normal)
• Target: 230-260 ng/mL
• Starting dose: 100 mcg CJC-1295 + 200 mcg Ipamorelin (nightly)
• Week 8 IGF-1: 180 ng/mL (suboptimal, below target)
• Action: Increase to 150 mcg CJC-1295 + 300 mcg Ipamorelin
• Recheck at Week 14 (6 weeks after adjustment)

Example 2: Optimal Response

• Patient: 50-year-old female, postmenopausal
• Baseline IGF-1: 120 ng/mL
• Target: 170-200 ng/mL
• Starting dose: 100 mcg CJC-1295 + 200 mcg Ipamorelin (nightly)
• Week 8 IGF-1: 185 ng/mL (optimal, within target)
• Action: MAINTAIN current dose; no change needed
• Continue monitoring every 3-6 months

Example 3: Supraphysiological Response

• Patient: 38-year-old male
• Baseline IGF-1: 200 ng/mL (normal)
• Target: 250-305 ng/mL (upper tertile for age 30-39)
• Starting dose: 100 mcg CJC-1295 + 200 mcg Ipamorelin (nightly)
• Week 8 IGF-1: 450 ng/mL (1.5x upper limit = 457; EXCESSIVE)
• Action: STOP CJC-1295 immediately; reassess after 4-week washout
• Consider genetic GHR polymorphism (hyperresponder); restart at 50% dose if desired

Metabolic Marker Adjustments

IGF-1 is the primary marker, but metabolic parameters also guide dosing.

Glucose Metabolism:

HOMA-IR (Insulin Resistance Index):

Clinical Recommendation: If glucose markers worsen significantly, prioritize metabolic health over GH optimization—reduce or discontinue CJC-1295.

Symptom-Based Adjustments

Positive Clinical Response (Supports Current Dose):

• Improved sleep quality and depth
• Enhanced workout recovery
• Increased energy and vitality
• Visible body composition improvements
• Improved skin texture and hydration
• No significant side effects

Negative Symptoms (Consider Dose Reduction):

• Persistent joint pain or swelling
• Carpal tunnel symptoms (numbness/tingling in hands)
• Significant fluid retention (edema)
• Headaches not resolving after Week 2
• New-onset hyperglycemia symptoms (excessive thirst, frequent urination)
• Sleep disruption (paradoxical insomnia)

No Response (Consider Dose Increase or Alternative):

• No change in IGF-1 after 8 weeks
• No subjective improvements in recovery, energy, or body composition
• Possible causes: Poor compliance, degraded peptide, fasting protocol not followed, genetic non-responder

Special Population Adjustments

Obesity (BMI >30):

• Challenge: Higher body fat associated with GH resistance (blunted response)
• Recommendation: Start with 25-50% higher dose (e.g., 150 mcg CJC-1295)
• Titration: May require doses at upper end of range to achieve target IGF-1
• Caution: Higher doses increase glucose/insulin risk—monitor closely

Hypothyroidism:

• Challenge: Untreated hypothyroidism blunts GH response
• Recommendation: Optimize thyroid replacement BEFORE starting CJC-1295
• Target TSH: 0.5-2.0 mIU/L for optimal GH axis function
• Titration: Once euthyroid, standard dosing applies

Genetic Hyperresponders:

• Identification: IGF-1 >1.5x upper limit on conservative dose
• Recommendation: Reduce dose by 50% or discontinue
• Genetic Basis: Polymorphisms in GHR (growth hormone receptor) may increase sensitivity
• Safety Priority: Avoid supraphysiological IGF-1 even if well-tolerated subjectively

Marker-Based Protocol Flowchart

START CJC-1295 PROTOCOL
         ↓
Week 0: Baseline Labs (IGF-1, glucose, HbA1c, thyroid)
         ↓
Week 0: Start Conservative Dose (100-150 mcg CJC-1295 + 100-200 mcg Ipamorelin)
         ↓
Week 6-8: Measure IGF-1, Fasting Glucose
         ↓
         ├─→ IGF-1 Below Target → INCREASE dose 25-50% → Recheck Week 14
         ├─→ IGF-1 Within Target → MAINTAIN dose → Monitor q3-6mo
         ├─→ IGF-1 Above Target (<1.5x) → REDUCE dose 25% → Recheck Week 14
         └─→ IGF-1 >1.5x Upper Limit → STOP → Washout 4 weeks → Reassess
         ↓
         ├─→ Glucose Rising → Reduce dose OR add metformin
         ├─→ Glucose Normal → Continue
         └─→ Glucose >125 mg/dL → STOP CJC-1295
         ↓
Week 12+: Assess Clinical Response
         ↓
         ├─→ Excellent response, no side effects → Continue
         ├─→ Side effects (edema, joint pain) → Reduce dose
         └─→ No response → Increase dose OR consider non-responder
         ↓
Months 3-6+: Monitor IGF-1 every 3-6 months, adjust as needed

Practical Example: 6-Month Titration Case Study

Patient Profile:

• 48-year-old male
• Baseline IGF-1: 140 ng/mL (low-normal for age)
• Goal: Body composition optimization, improved recovery
• Age-appropriate target IGF-1: 200-240 ng/mL

Week 0:

• Start: 100 mcg CJC-1295 + 200 mcg Ipamorelin (nightly before bed)

Week 8:

• IGF-1: 175 ng/mL (improved but below target)
• Fasting glucose: 92 mg/dL (normal)
• Clinical response: Modest sleep improvement, minimal body composition change
• Action: Increase to 150 mcg CJC-1295 + 300 mcg Ipamorelin

Week 14 (6 weeks after dose increase):

• IGF-1: 225 ng/mL (optimal, within target)
• Fasting glucose: 96 mg/dL (normal)
• Clinical response: Significant improvements in recovery, sleep quality, mild body composition changes
• Action: MAINTAIN current dose (150 mcg + 300 mcg)

Week 24 (Month 6):

• IGF-1: 230 ng/mL (stable, optimal)
• Fasting glucose: 98 mg/dL (normal)
• HbA1c: 5.3% (excellent)
• Clinical response: Continued benefits, no side effects
• Action: Continue current dose; plan 4-week off-cycle after Week 32

Outcome: Successful marker-based titration achieved optimal IGF-1 without supraphysiological elevation or metabolic disruption.

Summary: Marker-Based Dosing Best Practices

1. Always start conservative - Easier to titrate up than down
2. IGF-1 is primary biomarker - Target age-appropriate upper tertile
3. 6-8 week intervals - Allow time for IGF-1 to plateau before adjusting
4. Glucose monitoring is critical - GH antagonizes insulin; watch for dysregulation
5. Clinical response matters - If IGF-1 optimal but no benefit, reassess compliance/quality
6. Avoid supraphysiological IGF-1 - Risk exceeds benefit above 1.5x upper limit
7. Individualize based on age, sex, body composition - One size does NOT fit all
8. Cycle even with optimal dosing - 8-12 weeks on, 4 weeks off maintains receptor sensitivity

6. Reconstitution and Storage

6.1 Lyophilized Powder Storage (Before Reconstitution)

Unreconstituted CJC-1295 (Both Versions):

Short-Term Storage:

• Refrigerator: 2-8°C (36-46°F)
• Duration: Stable for several weeks to months
• Acceptable: For vials that will be used within a few months

Long-Term Storage:

• Freezer: -20°C to -80°C (-4°F to -112°F)
• Duration: Stable for several months to years
• Recommended: For long-term storage (>3 months)
• Environment: Dry, dark conditions; protect from moisture and light

Room Temperature:

• Lyophilized peptides can tolerate room temperature (20-25°C) for several weeks
• Not recommended for extended periods
• Refrigeration or freezing preferred

6.2 Reconstitution Procedure

Required Materials:

• CJC-1295 lyophilized vial (common sizes: 2 mg, 5 mg, 10 mg)
• Bacteriostatic Water (Recommended): Contains 0.9% benzyl alcohol preservative
• Alternative: Sterile water for injection (must use within 24-48 hours)
• Sterile syringe (1 mL or 3 mL)
• Alcohol swabs

Step-by-Step Reconstitution:

1. Sanitize:

   • Wipe rubber stoppers of CJC-1295 vial and BAC water vial with alcohol swabs
   • Allow to air dry (10-15 seconds)

2. Determine Reconstitution Volume:

   Example for 5 mg Vial of CJC-1295 Without DAC:

   • Add 2.5 mL BAC water → 2 mg/mL (2,000 mcg/mL)
   • For 100 mcg dose: 0.05 mL (5 units on insulin syringe)
   • For 200 mcg dose: 0.10 mL (10 units)

   Example for 2 mg Vial of CJC-1295 With DAC:

   • Add 2.0 mL BAC water → 1 mg/mL (1,000 mcg/mL)
   • For 2 mg dose (weekly): 2.0 mL (entire vial)

3. Draw Bacteriostatic Water:

   • Use sterile syringe to draw predetermined volume

4. Inject Water Slowly:

   • Insert needle into CJC-1295 vial
   • Inject BAC water slowly down the inside wall of vial
   • DO NOT spray directly onto powder

5. Gentle Swirling:

   • Swirl vial gently in circular motion
   • DO NOT SHAKE
   • Allow 1-2 minutes for complete dissolution

6. Visual Inspection:

   • Solution should be clear and colorless
   • No visible particles or cloudiness
   • If cloudy or discolored, discard

7. Label Vial:

   • Write reconstitution date
   • Note concentration (e.g., "2 mg/mL, reconstituted 12/22/2025")
   • Specify version (WITH DAC or WITHOUT DAC)

6.3 Post-Reconstitution Storage

Refrigeration is MANDATORY:

• Temperature: 2-8°C (36-46°F) - standard household refrigerator
• Duration: Use within 4-6 weeks when using bacteriostatic water; 24-48 hours if using sterile water
• Light Protection: Store in original vial or wrap in aluminum foil
• Position: Store upright to minimize stopper contact

DO NOT Store in Refrigerator Door:

• Temperature fluctuates with frequent opening/closing
• Use main shelf for stable temperature

Room Temperature Tolerance:

• Reconstituted CJC-1295 can tolerate brief room temperature exposure (hours)
• For travel: Use insulated cooler with ice packs
• Minimize time outside refrigeration

Critical Warnings:

• DO NOT FREEZE reconstituted CJC-1295: Freezing forms ice crystals that irreversibly denature peptides
• Discard After 4-6 Weeks: Even if refrigerated, bacterial growth risk increases
• Inspect Before Each Use: Discard if cloudy, discolored, or contains visible particles
• Do NOT Refreeze: Freeze-thaw cycles cause peptide degradation

7. Administration Methods and Pharmacokinetics

7.1 Subcutaneous Injection (Standard Route)

Why Subcutaneous?

• Established route for peptide hormones
• Consistent absorption
• Easy self-administration
• Good bioavailability for peptides

Injection Sites:

• Abdomen (Preferred): 2 inches lateral to navel
• Outer Thigh: Vastus lateralis
• Upper Arm: Deltoid (requires assistance)

Technique:

1. Clean site with alcohol swab, allow to dry
2. Pinch skin to create fold
3. Insert needle at 45-90° angle
4. Inject slowly (5-10 seconds)
5. Withdraw needle, apply gentle pressure
6. Rotate sites to prevent lipohypertrophy or lipoatrophy

7.2 Pharmacokinetics: WITH DAC vs WITHOUT DAC

CJC-1295 WITH DAC:

Absorption:

• Subcutaneous administration
• DAC modification allows albumin binding after absorption

Distribution:

• Volume of Distribution: Largely confined to vascular space due to albumin binding
• Albumin-bound CJC-1295 circulates in bloodstream

Metabolism:

• Slow release from albumin
• Enzymatic degradation by peptidases (minimal due to protective albumin binding)

Elimination:

• Half-Life: 5.8-8.1 days (some sources report 6-8 days)
• Clearance: Very slow (bound to albumin, which has ~19-day half-life)
• Route: Renal excretion (urine)

Pharmacodynamics:

• GH Elevation: Sustained for 6+ days
• IGF-1 Elevation: Sustained for 9-11 days
• Pattern: Continuous, non-pulsatile

CJC-1295 WITHOUT DAC (Mod GRF 1-29):

Absorption:

• Subcutaneous administration
• Rapid absorption into bloodstream

Distribution:

• Volume of Distribution: Extracellular fluid
• NOT significantly bound to albumin (no DAC)

Metabolism:

• Rapid enzymatic degradation by peptidases
• D-Ala² modification provides partial DPP-4 resistance
• Still much shorter half-life than WITH DAC version

Elimination:

• Half-Life: 30 minutes to 2 hours (most sources report ~30 minutes)
• Clearance: Rapid
• Route: Renal excretion

Pharmacodynamics:

• GH Elevation: 2-4 hours after injection
• IGF-1 Response: Gradual increase with repeated dosing
• Pattern: Pulsatile (mimics natural GH secretion)

7.3 Comparative Pharmacokinetics Table

7.4 Factors Affecting Response

Enhancers (Increase GH Response):

• Fasting State: Empty stomach critical (no food 90-120 min before, 30-60 min after)
• Low Glucose: Hyperglycemia blunts GH
• GH Secretagogues (for WITHOUT DAC): Synergy with ipamorelin, GHRP-6
• Exercise: Resistance training primes pituitary
• Adequate Sleep: GH response better when well-rested

Inhibitors (Decrease GH Response):

• Hyperglycemia: Elevated blood sugar blunts GH
• Elevated Free Fatty Acids: High-fat meals reduce response
• Obesity: Adiposity associated with blunted GH response
• Glucocorticoids: Suppress GH secretion
• Somatostatin Analogs: Directly inhibit GH release
• Advanced Age: Pituitary responsiveness declines

8. Cycling Protocols and Duration

8.1 CJC-1295 WITH DAC Cycling

Standard Protocol:

On-Cycle:

• Duration: 8-12 weeks (60-90 days)
• Frequency: Once weekly
• Dose: 1-2 mg per injection

Off-Cycle (Break Period):

• Duration: 4 weeks (30 days)
• Purpose: Allow GHRH receptors to reset; prevent desensitization

Annual Cycles:

• Most protocols recommend 3-4 cycles per year (8-12 weeks on, 4 weeks off)

Rationale for Cycling:

• Continuous GHRH receptor stimulation may lead to downregulation
• Breaks may restore receptor sensitivity
• Theoretically reduces long-term safety risks

8.2 CJC-1295 WITHOUT DAC Cycling

Standard Protocol:

On-Cycle:

• Duration: 8-12 weeks (60-90 days)
• Frequency: Daily or 5-days-on/2-days-off
• Dose: 100-200 mcg per injection, once or twice daily

Off-Cycle (Break Period):

• Duration: 4 weeks (30 days)
• Purpose: Prevent receptor desensitization

Frequency Options:

• Daily (7 days/week): Continuous daily injections
• 5 On, 2 Off: Inject Monday-Friday, skip weekends (convenient)

Annual Cycles:

• 3-4 cycles per year (8-12 weeks on, 4 weeks off)

8.3 Combination Cycling: CJC-1295 Without DAC + Ipamorelin

Most Popular Stack:

On-Cycle:

• CJC-1295 (No DAC): 100-200 mcg
• Ipamorelin: 200-300 mcg
• Frequency: Once daily (bedtime) or twice daily (AM + PM)
• Duration: 8-12 weeks

Off-Cycle:

• Duration: 4 weeks
• Complete break from both peptides

5-On-2-Off Weekly Pattern:

• Inject Monday-Friday
• Skip Saturday-Sunday
• Rationale: Prevents receptor desensitization while maintaining convenience

Why This Cycling Matters:

• Continuous stimulation → receptor downregulation → diminishing returns
• 30-day break allows receptors to "reset" and regain sensitivity
• Anecdotal reports suggest enhanced response after break

8.4 Response Timeline

What to Expect:

Important: Effects are subtle and gradual, not dramatic. CJC-1295 is not a substitute for proper diet, training, and sleep.

8.5 Discontinuation

No Withdrawal Symptoms:

• No physiological dependence on CJC-1295
• Abrupt discontinuation is safe
• No need to taper

What Happens After Stopping:

• GH and IGF-1 return to baseline within days (WITH DAC) to hours (WITHOUT DAC)
• Body composition changes may partially regress over 4-8 weeks
• Sleep quality may revert to pre-treatment levels

Restarting:

• No washout period required
• Can resume at previous effective dose

8.6 Protocol Integration: Ipamorelin + CJC-1295 Stack

The combination of CJC-1295 WITHOUT DAC (Mod GRF 1-29) with Ipamorelin represents the gold standard peptide stack for GH optimization. This section provides comprehensive protocol details for implementing this combination effectively.

Why This Stack is Preferred

Mechanistic Synergy:

Result: Two distinct pathways converging on pituitary somatotrophs produce 3-5 fold greater GH release than either peptide alone (true synergy).

Clinical Advantages:

1. Physiological Pattern: Both produce pulsatile GH release (mimics natural secretion)
2. Safety Profile: Ipamorelin has minimal cortisol/prolactin elevation (unlike GHRP-6, GHRP-2)
3. Clean Effect: No hunger stimulation (unlike GHRP-6)
4. Predictable Response: Well-characterized synergy allows reliable dosing
5. Convenience: Can be mixed in same syringe

Complete Stack Protocol

Standard Protocol (Most Users):

Aggressive Protocol (Body Composition/Recovery Focus):

Conservative Protocol (Anti-Aging/55+):

Reconstitution and Mixing Instructions

What You Need:

• CJC-1295 WITHOUT DAC vial (typically 2mg or 5mg)
• Ipamorelin vial (typically 5mg)
• Bacteriostatic water (BAC water)
• Insulin syringes (29-31 gauge, 0.5-1.0 mL)
• Alcohol swabs

Reconstitution (Each Vial Separately):

CJC-1295 (5mg vial):

1. Add 2.5 mL BAC water = 2000 mcg/mL concentration
2. For 100 mcg dose: Draw 0.05 mL (5 units on insulin syringe)
3. For 150 mcg dose: Draw 0.075 mL (7.5 units)
4. For 200 mcg dose: Draw 0.10 mL (10 units)

Ipamorelin (5mg vial):

1. Add 2.5 mL BAC water = 2000 mcg/mL concentration
2. For 200 mcg dose: Draw 0.10 mL (10 units)
3. For 300 mcg dose: Draw 0.15 mL (15 units)

Mixing in Same Syringe:

1. Draw prescribed CJC-1295 dose into insulin syringe
2. Draw prescribed Ipamorelin dose into SAME syringe
3. Total volume for standard protocol: ~0.175 mL (17.5 units)
4. Gently mix (do not shake)
5. Inject immediately subcutaneously

Storage After Reconstitution:

• Refrigerate at 2-8°C (36-46°F)
• Use within 4-6 weeks
• DO NOT FREEZE reconstituted peptides

Timing and Fasting Protocol

Critical Timing Requirements:

2 hours before injection: STOP eating (begin fast)
                          ↓
90 minutes: No food, water okay
                          ↓
Injection time: Subcutaneous injection (abdomen preferred)
                          ↓
30-60 minutes after: Continue fast
                          ↓
Post-fast: May eat (ideally protein-rich meal if AM dose)

Why Fasting Matters:

• Elevated glucose BLUNTS GH response (glucose = somatostatin release)
• Elevated insulin INHIBITS GH secretion
• Empty stomach ensures maximum pituitary response
• This is the MOST important compliance factor for stack efficacy

Optimal Timing by Goal:

Expected Response Timeline

What to Expect (Realistic Expectations):

Blood Marker Changes:

• IGF-1: Expect 20-50% increase from baseline (within age-appropriate range)
• IGF-1 effect detectable by week 4-6
• Maximum IGF-1 effect by week 8-12

Important Notes:

• Effects are SUBTLE and GRADUAL - not dramatic overnight changes
• Diet, training, and sleep quality significantly affect results
• Non-responders exist (~10-15%) - may need protocol adjustment or alternative approach
• Realistic expectation: 1-3% body fat reduction, modest lean mass gain over 8-12 weeks

Troubleshooting the Stack

Suboptimal Response (IGF-1 not increasing):

Side Effects Management:

Stack Variations

Alternative GHRP Options (Instead of Ipamorelin):

Recovery-Focused Stack (Adding BPC-157/TB-500):

Note: BPC-157 and TB-500 do not interact with CJC-1295/Ipamorelin; they address different repair pathways.

Stack Summary Quick Reference

Standard Stack (Copy This Protocol):

IPAMORELIN + CJC-1295 STACK
============================
Peptides: CJC-1295 WITHOUT DAC (Mod GRF 1-29) + Ipamorelin
Doses: CJC-1295 100-150 mcg + Ipamorelin 200-300 mcg
Mixed: Yes, same syringe
Route: Subcutaneous (abdomen)
Timing: 30-60 minutes before sleep
Fasting: 2 hours before, 30-60 min after
Frequency: Once daily (or twice daily for aggressive goals)
Cycle: 8-12 weeks ON, 4 weeks OFF
Monitoring: IGF-1 at baseline, week 6-8
Target: Age-appropriate upper tertile IGF-1

9. Legal and Regulatory Status

9.1 FDA Status

Not FDA-Approved:

• CJC-1295 (both versions) has NEVER received FDA approval for any therapeutic indication
• Classified as Investigational New Drug (IND)
• Cannot be legally marketed as a drug or dietary supplement in United States

Clinical Development Status:

• Phase I/II trials completed for WITH DAC version
• Development discontinued following subject death in trials
• No current FDA-approved CJC-1295 product exists

9.2 FDA Safety Concerns (2024 Briefing Documents)

Pharmacy Compounding Advisory Committee (PCAC) Meetings:

The FDA has flagged CJC-1295 for safety concerns in compounding contexts:

1. Cardiovascular Risks:

• Increased heart rate
• Systemic vasodilatory reaction (flushing, warmth, transient hypotension)

2. Immunogenicity:

• Risk of allergic reactions, potentially life-threatening (anaphylaxis)

3. Categorical Status in Limbo:

• FDA has not determined whether CJC-1295 will be included on the 503A bulks list
• Compounding pharmacies await regulatory clarification

9.3 Availability and Legal Status

Compounding Pharmacies (503A):

• CJC-1295 is available through 503A compounding pharmacies
• Compounded for individual patients with prescriptions
• Off-label use: Physicians can prescribe for anti-aging, wellness, body composition

Research Chemical Suppliers:

• Many online suppliers sell CJC-1295 "for research purposes only"
• Quality, purity, and dosing accuracy vary widely
• No regulatory oversight of research chemical market

Legal Gray Zone:

• Purchase and possession for "research" may be legal
• Human self-administration exists in regulatory ambiguity
• Not a controlled substance (unlike growth hormone, which is Schedule III in some contexts)

9.4 World Anti-Doping Agency (WADA) Prohibition

Banned Substance:

• CJC-1295 (both versions) is PROHIBITED by WADA
• Category: S2. Peptide Hormones, Growth Factors, Related Substances, and Mimetics
  • Specifically listed under "Growth Hormone Releasing Factors (GHRF)" and their analogs
• Banned at all times (in-competition and out-of-competition)

Detection:

• Sophisticated testing methods (LC-MS/MS) can detect CJC-1295 and metabolites
• GH isoform testing can reveal exogenous GH stimulation
• Detection window: Days to weeks depending on version and dose

Consequences for Athletes:

• Anti-doping rule violation
• Disqualification, medal forfeiture, competition bans (typically 2-4 years)
• Applies to Olympic sports, professional leagues, NCAA, etc.

Athlete Warning: Competitive athletes subject to drug testing should NEVER use CJC-1295 (either version) under any circumstances.

9.5 International Regulations

Variability by Country:

• United States: Research chemical; available via compounding
• Canada: Similar to US; prescription required for compounded forms
• European Union: Regulations vary; generally more restricted
• Australia: Prescription required; therapeutic goods regulation
• United Kingdom: Prescription-only medicine (unlicensed)

Import/Export:

• Importation may be restricted in some countries
• Check destination country regulations before traveling with CJC-1295

9.6 Insurance Coverage

Not Covered:

• CJC-1295 is NOT covered by insurance (not FDA-approved)
• Out-of-Pocket Cost:
  • WITH DAC: $200-$400 per month
  • WITHOUT DAC + Ipamorelin: $250-$500 per month
  • Varies by source, dose, and combination

10. Summary and Recommendations

10.1 Evidence-Based Summary

CJC-1295 is a synthetic GHRH analog with strategic amino acid modifications that enhance stability and prolong biological activity. It exists in two pharmacologically distinct forms:

CJC-1295 WITH DAC:

• Long-acting (6-8 day half-life)
• Sustained, non-pulsatile GH elevation
• Evaluated in Phase I/II clinical trials with positive efficacy results
• Development discontinued following subject death (unclear causality)
• Once weekly dosing (convenient)
• FDA safety concerns regarding CV risks and immunogenicity

CJC-1295 WITHOUT DAC (Mod GRF 1-29):

• Short-acting (30-minute half-life)
• Pulsatile GH release (mimics natural GHRH)
• Limited clinical trial data (mostly anecdotal evidence)
• Daily or twice daily dosing (less convenient)
• Often combined with ipamorelin for synergistic effects
• Appears safer due to shorter half-life (fewer prolonged exposure risks)

Strengths:

• Well-characterized mechanism (GHRH receptor agonism)
• Clinical trial data supports GH/IGF-1 elevation (WITH DAC)
• Synergy with GHRPs (WITHOUT DAC + ipamorelin)
• Modifications enhance stability vs natural GHRH

Limitations:

• No FDA approval (either version)
• Development discontinued (WITH DAC)
• Limited long-term safety data
• Subject death in trials (WITH DAC)
• FDA safety warnings (CV, immunogenicity)
• WADA prohibited
• Quality control issues (research chemical market)

10.2 Which Version Should You Use?

CJC-1295 WITH DAC:

Consider IF:

• Convenience is paramount (once weekly dosing)
• You accept risk of sustained, non-physiological GH pattern
• You are NOT combining with GHRPs (ipamorelin, GHRP-6)

Avoid IF:

• You have cardiovascular disease or risk factors
• You prefer physiological pulsatile GH pattern
• You want ability to quickly discontinue if side effects occur
• You plan to combine with ipamorelin (conflicting patterns)

CJC-1295 WITHOUT DAC (Mod GRF 1-29):

Consider IF:

• You want to mimic natural pulsatile GH release
• You plan to combine with ipamorelin for synergy
• You prefer shorter half-life for safety
• You can commit to daily (or twice daily) injections

Avoid IF:

• Daily injections are impractical
• You cannot maintain strict fasting protocols

Current Trend: Most practitioners and users prefer CJC-1295 WITHOUT DAC + Ipamorelin combination due to:

• Physiological pulsatile pattern
• Synergistic effects
• Shorter half-life (safer)
• Better tolerability (anecdotal)

10.3 Who Might Consider CJC-1295?

Potential Candidates (Research/Off-Label Context):

1. Adults with Age-Related GH Decline:

   • Low-normal IGF-1 levels
   • Symptoms: Fatigue, poor recovery, loss of lean mass, increased body fat
   • Failed conservative interventions

2. Athletes and Bodybuilders (Non-Competitive):

   • Seeking enhanced recovery and body composition
   • NOT subject to WADA testing

3. Individuals Seeking Alternatives to rhGH:

   • Concerned about risks/costs of exogenous GH
   • Prefer physiological GH stimulation

4. Combination Therapy Users:

   • Those using ipamorelin seeking synergistic effects (WITHOUT DAC only)

10.4 Who Should AVOID CJC-1295?

Absolute Contraindications:

• Active cancer or malignancy
• History of cancer (within 5 years, or consult oncologist)
• Critical illness
• Known allergy to CJC-1295
• Competitive athletes subject to WADA testing
• Cardiovascular disease (especially for WITH DAC)

Relative Contraindications:

• Pregnancy or breastfeeding
• Diabetes (requires close monitoring)
• Diabetic retinopathy
• Hypothyroidism (optimize thyroid first)
• Sleep apnea (treat before starting)
• Age <18 years

10.5 Clinical Recommendations

If Considering CJC-1295:

1. Medical Consultation:

   • Consult qualified healthcare provider
   • Baseline labs:
     • IGF-1 level
     • Fasting glucose and HbA1c
     • Thyroid function (TSH, free T4)
     • Complete blood count (CBC)
     • Comprehensive metabolic panel
     • ECG (if CV risk factors)

2. Choose Version Carefully:

   • WITHOUT DAC preferred for most users (pulsatile, safer)
   • Consider WITH DAC only if convenience outweighs risks

3. Start Low, Go Slow:

   • WITHOUT DAC: Start with 100 mcg, titrate to 100-200 mcg
   • WITH DAC: Start with 1 mg weekly, assess tolerance
   • Target IGF-1 in mid-normal range for age (not supraphysiological)

4. Optimize Administration:

   • Empty stomach (90-120 min fasted before, 30-60 min after)
   • Bedtime dosing (aligns with natural GH pulse)
   • Consider combination with ipamorelin (WITHOUT DAC only)

5. Monitoring:

   • Reassess at 3 months: IGF-1, glucose, subjective response
   • Ongoing monitoring every 6-12 months if continuing
   • Discontinue if no benefit by 8-12 weeks

6. Lifestyle Foundation:

   • CJC-1295 is NOT a substitute for fundamentals
   • Maintain:
     • Resistance training (3-5x/week)
     • Adequate protein (1.6-2.2 g/kg)
     • Quality sleep (7-9 hours)
     • Stress management

10.6 Future Research Directions

Critical Studies Needed:

1. Large RCTs: Placebo-controlled trials for body composition in healthy adults
2. Long-Term Safety: 5-10 year studies assessing cancer risk, CV outcomes
3. WITH DAC vs WITHOUT DAC: Head-to-head comparison for safety and efficacy
4. Combination Therapy: Rigorous trials of WITHOUT DAC + ipamorelin vs monotherapy
5. Optimal Dosing: Systematic dose-response studies
6. Causality Investigation: Clarify relationship (if any) between subject death and WITH DAC

10.7 Final Disclaimer

This document is for educational and research purposes only. CJC-1295 (both versions) is NOT FDA-approved for human therapeutic use. Clinical development was discontinued following safety concerns. Any use of CJC-1295 is off-label and should only be undertaken with the guidance of a qualified, licensed healthcare provider who can assess individual risks and benefits. Competitive athletes subject to WADA testing must NOT use CJC-1295. This information should not be construed as medical advice. The authors and publishers assume no liability for actions taken based on this information.

Stacking Insights

• that's because it increases your metabolic rate so when you take CJC 1295 with Memorial and all other things being equal you burn more calories than you did before so let's

11. References and Sources

Chemical Structure and Modifications

1. CJC-1295 - Wikipedia
2. CJC-1295 With DAC vs. Without DAC - Revolution Health
3. CJC-1295 Without DAC: Modified GRF (1-29) - Wholesale Peptide
4. CJC-1295 DAC vs. CJC-1295 No DAC - Peptides.org
5. CJC-1295 DAC vs No DAC - Livv Natural
6. CJC-1295 DAC vs No DAC: Key Differences - Swolverine

Mechanism of Action

7. What is CJC-1295 Ipamorelin? - Oath Peptides
8. GHRPs and CJC-1295: Boosting Growth Hormone - Wholesale Peptide
9. CJC-1295 Peptide - Paragon Sports Medicine
10. CJC-1295 Mod-GRF: Enhance Growth Hormone Secretion - Wholesale Peptide

Dosing Protocols

11. CJC‑1295 For Beginners - Swolverine
12. Personalized Growth Hormone Peptide Dosing - Age Well Atlanta
13. CJC-1295 Dosage and Cycle Length - Imperium Health
14. CJC-1295 Dosage Calculator - Peptides.org
15. CJC-1295 W/O DAC Dosing & Need to Know's - Peptide Initiative

Clinical Trials and Research

16. Prolonged stimulation of GH and IGF-I by CJC-1295 - PubMed
17. CJC-1295 Ipamorelin: Research, Safety, Results - BodySpec
18. CJC-1295 + Ipamorelin: Benefits, Safety [2025] - Innerbody
19. CJC-1295 | Reviews, Clinical Trials, and Safety - Peptides.org
20. FDA Presentation – CJC-1295 - FDA
21. FDA Briefing Document PCAC Meeting - FDA

Safety and Side Effects

22. CJC-1295 Safety Profile - Peptide Initiative
23. Safety Profile and CJC 1295 Side Effects - Elements Arms
24. CJC-1295 Side Effects, Complications - Peptides.org
25. CJC-1295 Safety Guide - Holistic Medical Wellness

Reconstitution and Storage

26. How to Reconstitute CJC 1295 - Sarms.io
27. How to Reconstitute CJC 1295 Ipamorelin 5mg - Real Peptides
28. CJC-1295 No-DAC + Ipamorelin Dosage Guide - Peptide Dosages
29. Mixing and Injection Instructions - Virility Inc

Pharmacokinetics

30. CJC 1295 Modified GRF (1-29) - FDA

Cycling and Combination Protocols

31. Why You Should Cycle CJC-1295: The 60–90 Day Protocol - Revolution Health
32. Ipamorelin + CJC-1295: Peptide Combo Explained - Swolverine
33. CJC-1295 Ipamorelin Dosage - Alpha Rejuvenation
34. Ipamorelin + CJC 1295 Stack: The Dynamic Duo - Muscle and Brawn
35. CJC 1295 Ipamorelin Dosage Guide - ThinWorks

Document Version: 3.0 Last Updated: January 5, 2026 Prepared For: DosingIQ Research Library Classification: Educational/Research Only - Not Medical Advice

Total Word Count: ~35,000 words Reading Time: ~130 minutes

Version 2.0 Additions:

• Goal Archetype Integration (GH Release, Recovery, Anti-Aging, Body Composition)
• Age-Stratified Dosing Guidelines (Under 40, 40-55, 55+)
• Expanded Drug Interactions (Diabetes medications, Somatostatin, Ipamorelin synergy, WITH/WITHOUT DAC)
• Comprehensive Bloodwork Monitoring Protocol (IGF-1 targets, glucose/insulin, thyroid)
• Protocol Integration: Ipamorelin + CJC-1295 Stack Details

Version 3.0 Additions (EXPANSION-PLAN Enhancement):

• Sex-Specific Considerations and Dosing - Comprehensive male/female physiological differences, estrogen-IGF-1 paradox, hormone therapy interactions, sex-specific monitoring protocols
• Marker-Based Dosing Protocol - Advanced IGF-1-guided titration, metabolic marker adjustments, symptom-based modifications, individualized dosing flowchart with case studies
• Enhanced Goal Archetype Protocols - Practical biohacker implementations including:
  • Complete 12-week body recomposition protocol with training, nutrition, and peptide timing
  • Hypertrophy optimization protocol with post-workout peptide timing
  • Injury recovery stack with BPC-157/TB-500 integration and rehabilitation guidance
• GH Decline by Age Table - Quantitative age-related GH secretion decline data
• Expanded Practical Applications - Real-world protocols with expected timelines, realistic outcomes, and troubleshooting guidance

Key Enhancements Summary: This comprehensive expansion transforms CJC-1295 guidance from theoretical dosing protocols to actionable, individualized strategies. The addition of sex-specific physiology, marker-based titration, and complete goal-oriented protocols provides practitioners and biohackers with evidence-based frameworks for safe, effective GH optimization across diverse applications (muscle building, fat loss, recovery, anti-aging, injury rehabilitation).

Target Audience:

• Advanced biohackers implementing GH peptide protocols
• Healthcare practitioners prescribing peptide therapy
• Athletes and bodybuilders seeking evidence-based performance optimization
• Individuals with age-related GH decline seeking conservative hormone optimization

END OF DOCUMENT